Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Non-randomized and Open-label Phase 3 Study Evaluating the Efficacy, Safety and Tolerability of Intravitreal Aflibercept in Japanese Patients With Neovascular Glaucoma (NVG)

NCT03639675 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT03639675
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03639675 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Non-randomized and Open-label Phase 3 Study Evaluating the Efficacy, Safety and Tolerability of Intravitreal Aflibercept in Japanese Patients With Neovascular Glaucoma (NVG)
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
October 3, 2018
Completion date
March 14, 2019
Enrollment
16 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

glaucoma, neovascular